ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT00555919
First received: November 8, 2007
Last updated: April 1, 2014
Last verified: April 2014

November 8, 2007
April 1, 2014
March 2008
April 2010   (final data collection date for primary outcome measure)
To evaluate efficacy (clinical benefit) of two doses of ZK PRA (25 mg and 100 mg) when administered once daily p.o. [ Time Frame: month 3, month 6 ] [ Designated as safety issue: No ]
Proof of Concept: Evaluation of efficacy (clinical benefit) of two doses of ZK PRA (25 mg and 100 mg) when administered once daily p.o. [ Time Frame: 6 month or until disease progression ]
Complete list of historical versions of study NCT00555919 on ClinicalTrials.gov Archive Site
  • To evaluate safety and tolerability [ Time Frame: ongoing thoughout the trial ] [ Designated as safety issue: Yes ]
  • To evaluate the pharmacokinetics of ZK PRA [ Time Frame: baseline, month1,2,6 ] [ Designated as safety issue: No ]
  • To evaluate the effect of ZK PRA on quality of life (QoL) [ Time Frame: baseline, month 1,2,3,4,5,6 ] [ Designated as safety issue: No ]
  • To perform exploratory analysis of biomarkers [ Time Frame: baseline, month 1, 3 ] [ Designated as safety issue: No ]
  • Progression-free survival (PFS) [ Time Frame: end of study ] [ Designated as safety issue: No ]
  • Objective response rate (ORR) / Duration of response - in the subset of patients with measurable disease [ Time Frame: end of study ] [ Designated as safety issue: No ]
  • Duration of Clinical Benefit [ Time Frame: end of study ] [ Designated as safety issue: No ]
  • Overall Survival (OS) [ Time Frame: end of study ] [ Designated as safety issue: No ]
  • Evaluation of safety and tolerability [ Time Frame: 6 month or until disease progression ]
  • Pharmacokinetics of ZK PRA [ Time Frame: 6 month or until disease progression ]
  • Effect of ZK PRA on quality of life (QoL) [ Time Frame: 6 month or until disease progression ]
  • Exploratory analysis of biomarkers [ Time Frame: 6 month or until disease progression ]
Not Provided
Not Provided
 
ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer
Randomized Phase II Study to Investigate the Efficacy, Safety and Tolerability of ZK 230211 (25 mg vs. 100 mg) as Second-line Endocrine Therapy for Postmenopausal Women With Hormone Receptor-positive Metastatic Breast Cancer

Randomized phase II study to investigate the efficacy, safety and tolerability of ZK 230211 (100 mg vs. 25 mg) as second-line endocrine therapy for postmenopausal women with hormone receptor-positive metastatic breast cancer.Once the cancer has spread beyond the lymph nodes to areas such as e.g. the skin, soft tissues, lung, and liver it is called metastatic breast cancer. Patients who have been diagnosed with metastatic breast cancer that has progressed since their previous cancer treatment and that cannot be removed completely by surgery are eligible to be treated within this trial.Treatment with a new drug called Progesterone Receptor Antagonist ZK 230211 (ZK PRA) targets the progesterone receptor which may be expressed on breast cancer tumour cells. Therefore only patients with this progesterone receptor on their tumour cells can be included in this study.Progesterone receptor antagonists (including onapristone) have already shown efficacy in postmenopausal women with advanced breast cancer (Klijn et al. 2000). This phase II study investigates the efficacy (proof of concept), safety and tolerability of ZK PRA at two dose levels (25 mg and 100 mg) before initiating pivotal phase III trials.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Metastatic Breast Cancer
  • Drug: Lonaprisan (ZK 230211, BAY86-5044)
    25 mg daily oral treatment
  • Drug: Lonaprisan (ZK 230211, BAY86-5044)
    100 mg daily oral treatment
  • Experimental: Arm 1
    Intervention: Drug: Lonaprisan (ZK 230211, BAY86-5044)
  • Experimental: Arm 2
    Intervention: Drug: Lonaprisan (ZK 230211, BAY86-5044)
Jonat W, Bachelot T, Ruhstaller T, Kuss I, Reimann U, Robertson JF. Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. Ann Oncol. 2013 Oct;24(10):2543-8. doi: 10.1093/annonc/mdt216. Epub 2013 Jun 20.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
68
March 2011
April 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Postmenopausal women defined as: aged >/= 50 years with amenorrhea for at least 12 months or aged < 50 years with 6 months of spontaneous amenorrhea and follicle stimulating hormone (FSH) level within postmenopausal range (> 40 mIU/ml) or having undergone bilateral oophorectomy
  • Histologically or cytologically confirmed breast cancer
  • Metastatic breast cancer (Stage IV according to UICC - Union Internationale Contre Cancer - criteria, Version 6)
  • Progesterone receptor-positive tumors
  • Patients must be considered candidates for endocrine therapy (no other therapies for breast cancer are required)
  • Disease progression after first-line endocrine therapy for advanced breast cancer (i.e. with tumor remission or stabilization lasting at least 3 months under endocrine therapy)
  • At least one measurable or non-measurable tumor lesion (according to RECIST criteria)
  • WHO Performance status 1
  • Adequate function of major organs and systems:

    • Hematopoietic:

      • Hemoglobin: 10 g/dL
      • Absolute neutrophil count: 1,500/mm3
      • Platelet count: 100,000/mm3
    • Hepatic:

      • Total bilirubin: 1.5 times the upper limit of normal
      • AST/ALT: 2.5 times the upper limit of normal
    • Renal: Creatinine: 1.5 times the upper limit of normal
    • Gynecological: Endometrial thickness (in non-hysterectomized women) </= 10 mm double layer
    • No other uncontrolled concurrent illness
  • Adequate recovery from previous surgery, radiation and chemotherapy
  • Written informed consent

Exclusion Criteria:

  • Presence of any of the following conditions:

    • life-threatening metastatic visceral disease (extensive hepatic involvement)
    • any metastases to the central nervous system (CNS)
    • pulmonary lymphangitic metastases involving more than 50% of the lung
  • More than one prior endocrine treatment for advanced breast cancer
  • Previous combination of endocrine treatment with any other type of treatment (except chemotherapy), or previous sequential endocrine treatments (if there was disease progression between treatments) are not permitted in this trial.
  • Patients with breast cancer HER-2 positive or with unknown HER-2 status are not eligible.
  • Malignancies or history of prior malignancy other than carcinoma in situ of the cervix or uterus, or basal and squamous cell carcinoma of the skin
  • Intake of CYP3A4 inhibitors less than 2 weeks before start of study treatment
  • A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 milliseconds (ms)
  • A history of additional risk factors for TdP (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
  • The use of concomitant medications that prolong the QT/QTc interval
  • Other investigational drug therapies less than 4 weeks or at least 5 half-lives before start of study treatment (less than 4 weeks for faslodex and less than 2 weeks for any other endocrine therapy)
  • Expectation that the patient will not be able to complete at least 3 months of therapy
  • Unwillingness or inability to comply with the protocol
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Austria,   Finland,   France,   Germany,   Italy,   Poland,   Spain,   Sweden,   Switzerland,   United Kingdom
 
NCT00555919
91484, 2005-005581-36, 309821
No
Bayer
Bayer
Not Provided
Study Director: Bayer Study Director Bayer
Bayer
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP